P

Philips

Makes medical devices and personal health products

Personal Health Business Zone Leader

Full-TimeUpdated Deadline 11/30/26
No salary listed
Expert
MBA
Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia
In Person
Business & Strategy

About the job

Requirements
  • At least 18 years of overall experience with a background in general management, sales, and marketing in the FMCG or FMCD industry.
  • Experience in P&L management, including revenue and margin management (top line and EBITDA).
  • Experience managing a commercial business and the ability to build and manage a sales-focused organization.
  • Experience developing new business models and digital, online, and offline channel mixes.
  • Problem-solving skills and the ability to find solutions to difficult or complex issues; drives continuous improvement through Lean.
  • A deep understanding of the global business environment and end-user insights.
  • Ability to communicate effectively with C-level stakeholders.
  • A strong growth mindset and experience as a turnaround specialist.
  • Results-oriented approach and personal accountability for delivering results; ability to collaborate with and influence stakeholders; strong communication and interpersonal skills.
  • Ability to leverage capabilities and work across internal and external boundaries to maximize value through simple solutions.
  • Experience managing teams toward common goals and developing people's skills and growth.
  • Ability to bring people together and align them around common goals, leveraging Philips capabilities independently of organizational structures and reporting lines.
Responsibilities
  • Co-own the P&L for the respective business cluster in the market.
  • Contribute to the Market SPOR process in line with the annual cycle, translating strategy into targets and ensuring capacity and investments are available to achieve them; arrange appropriate and affordable capabilities for markets and define a specific Personal Health commercial strategy based on strategic plans.
  • Drive sales growth by developing and using omni-channels, driving Direct-to-Consumer digital activation, and optimizing the commercial triangle of Sales, Marketing, and Trade Marketing.
  • Bring BMC plans to the Market MT to ensure integration with and support from functional leaders, and align the BMC plan with the Market Leader.
  • Drive consumer engagement by understanding market evolution and providing effective sales propositions and an optimized portfolio of products, solutions, and services based on local needs, supported by meaningful consumer communication and engagement plans.
  • Champion Philips compliance with General Business Principles in the marketplace.
  • Demonstrate Philips leadership competencies and behaviors in daily work.
  • Define the Market Personal Health strategic plan.
  • Own the overall value creation and extraction model in the market through maximizing the commercial triangle of Sales, Marketing, and Trade Shopper Marketing.
  • Develop and execute a market growth plan in close partnership with global businesses.
  • Develop and implement sales account strategies to meet financial objectives.
  • Provide the Business Cluster with market information, including current trends, sales techniques, and applications of Personal Health solutions along the health continuum in the market.
  • Maintain ongoing dialogue with global businesses about performance, forecasts, market trends, competition, and growth opportunities.
  • Activate the entire local market commercial organization to sell and position the portfolio to customers.
  • Drive Local Marketing Strategy and Planning through the Marketing team, own advertising and promotion spend, Professional Marketing for OHC and MCC, and ensure effective BMC planning.
  • Ensure portfolio marketing, including the omni-channel calendar in which NPI sits, and manage the portfolio through SKU rationalization and product, solution, and service phase-ins and phase-outs.
  • Develop and manage effective relationships with top customers, channel partners, end users, and stakeholders.
  • Lead the Consumer domain for the Philips organization in the market, enabling access to different value propositions and digital activation capabilities within and outside Personal Health through a strong Direct-to-Consumer organization.
  • Drive continuous improvement by applying Lean.
  • Build a strong Personal Health team, with particular focus on Direct-to-Consumer and digital activation capabilities.
  • Champion personalization of healthcare and connect the consumer world to Health Systems business clusters.

About the company

Philips makes medical equipment and software for hospitals and care providers, along with personal health products for consumers. Its hospital portfolio spans MRI and CT scanners, ultrasound, image-guided treatment systems and patient monitors, while Sonicare and Avent cover oral health and baby care. Clinical software connects medical images and patient data across care teams, and the company earns revenue from equipment, software, maintenance and consumer product sales. It works with health systems through long-term technology and service partnerships, including solutions for care at home. Founded in 1891, Philips is headquartered in Amsterdam, the Netherlands.

Company Size

10,001+

Company Stage

Acquired

Total Funding

$164.7M

Headquarters

Murrysville, Pennsylvania

Founded

1891

Get referred to Philips

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand improved: Philips reported 4% comparable group sales growth for Q2 2026 in July 2026.
  • Software expertise has room to develop: software and data science comprised about half Philips' research effort in 2025.
  • Manufacturing expansion has backing: Philips reiterated a $150 million North American investment plan in February 2026.

What critics are saying

  • US sleep-device sales remain restricted: Philips Respironics must meet consent-decree requirements before resuming new sleep-therapy device sales.
  • Underlying earnings weakened: Philips' July 2026 report shows Q2 adjusted earnings fell slightly excluding its US tariff refund.
  • Central teams face cost pressure: February 2026 plans target 15% to 20% lower central-function costs at Philips.

What makes Philips unique

  • MRI avoids helium refills: Philips says its sealed BlueSeal magnets use seven liters rather than conventional systems' 1,500.
  • Inventions form a substantial asset base: Philips reports 53,000 patent rights across its technology portfolio.
  • The employer's name spans independent businesses: Philips licenses its brands across multiple product categories to outside partners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Unlimited Paid Time Off
  • Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.